^
    Back
    Association details:
    Biomarker:PD-L1 overexpression + BRAF V600E
    Cancer:Lung Adenocarcinoma
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Front Oncol
    Title:

    Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report

    Published date:
    06/10/2021
    Excerpt:
    ...case of 62-year-old female non-smoker with high PD-L1 expression and BRAF V600E mutated NSCLC….durable response to ICPi in BRAF V600E non-smoking lung adenocarcinoma with PFS of 20 months under first-line atezolizumab plus chemotherapy treatment.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.3389/fonc.2021.634920